Results 1 to 10 of about 490,180 (313)

Defining RASopathy

Disease Models & Mechanisms, 2022
The term RASopathy was originally created to describe a phenotypically similar group of medical genetic syndromes caused by germline pathogenic variants in components of the RAS/mitogen-activated protein kinase (RAS/MAPK) pathway. In defining a RASopathy
Katherine A. Rauen
doaj   +1 more source

Functional profiling of live melanoma samples using a novel automated platform. [PDF]

PLoS ONE, 2012
This proof-of-concept study was designed to determine if functional, pharmacodynamic profiles relevant to targeted therapy could be derived from live human melanoma samples using a novel automated platform.A series of 13 melanoma cell lines was briefly ...
Adam Schayowitz, Greg Bertenshaw, Emiko Jeffries, Timothy Schatz, James Cotton, Jessie Villanueva, Meenhard Herlyn, Clemens Krepler, Adina Vultur, Wei Xu, Gordon H Yu, Lynn Schuchter, Douglas P Clark   +12 more
doaj   +1 more source

Precision drugging of the MAPK pathway in head and neck cancer

npj Genomic Medicine, 2022
The mitogen-activating protein kinase (MAPK) pathway is central for cell proliferation, differentiation, and senescence. In human, germline defects of the pathway contribute to developmental and congenital head and neck disorders.
Hoi-Lam Ngan, Chun-Ho Law, Yannie Chung Yan Choi, Jenny Yu-Sum Chan, Vivian Wai Yan Lui   +4 more
doaj   +1 more source

Ecological inducers of the yeast filamentous growth pathway reveal environment-dependent roles for pathway components

mSphere, 2023
Signaling modules, such as mitogen-activated protein kinase (MAPK) pathways, are evolutionarily conserved drivers of cell differentiation and stress responses.
Matthew D. Vandermeulen, Paul J. Cullen
doaj   +1 more source

Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma

Molecular Therapy: Oncolytics, 2020
BRAF and MEK inhibitors significantly prolong progression-free survival in patients with BRAF mutant melanoma. However, most patients quickly develop drug resistance.
Kun Zhao, Yanrong Lu, Younan Chen, Jingqiu Cheng, Wengeng Zhang   +4 more
doaj   +1 more source

The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway

Heliyon, 2023
Objective: The topoisomerase inhibitor CPT-11 has been applied in treatment of multiple cancer types. Here, we probed into the possible mechanism of CPT-11 in affecting growth and metastasis of lung cancer (LC) cells, with involvement of the EGFR/MAPK ...
Yingqiu Yin, Junling Xie, Feng Peng, Liming Tan, Yun Xiao, Huiying Zheng, Lingzhi Yin, Huijing Situ, Shanqiang Zhang   +8 more
doaj   +1 more source

Differential effects of mitogen-activated protein kinase pathway inhibitors on P-glycoprotein activation

ADMET and DMPK, 2015
The aim of this study was to evaluate the effects of the mitogen-activated protein kinase (MAPK) pathway inhibitors SB203580, CMPD-1, SB239063, SP600125, and FR180204 on the activity of P-glycoprotein (P-gp) and to assess whether the MAPK pathway affects
Hirokazu Wakuda, Shino Miyauchi, Kana Maruyama, Satomi Kagota, Kazuki Nakamura, Keizo Umegaki, Shizuo Yamada, Kazumasa Shinozuka   +7 more
doaj   +1 more source

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis

Cell Communication and Signaling, 2022
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the “L-group” histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are detectable in nearly all LCH lesions. However, the pathogenic roles of MAPK
Xue-min Gao, Jian Li, Xin-xin Cao
doaj   +1 more source

FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells [PDF]

, 2014
Receptor Tyrosine Kinases (RTKs) and Focal Adhesion Kinase (FAK) regulate multiple signalling pathways, including mitogen-activated protein (MAP) kinase pathway. FAK interacts with several RTKs but little is known about how FAK regulates their downstream
A Bergmann, A Boulay, A Ueda, AC Dar, B Corkery, B Gabriel, BA Edgar, BA Hay, BJ Dickson, C Grabbe, CJ Marshall, D Tenenbaum, DD Schlaepfer, DJ Sieg, E Macia, E Rainero, E Rainero, E Sandilands, E Sandilands, Emma Sandilands, FD Karim, FJ Diaz-Benjumea, G Adam, GL Fox, I Bongarzone, I Plaza-Menacho, I Rebay, Iain MacPherson, IH Gelman, J Cordero, J Fujimoto, J Verdu, J Zhao, Jesica Diaz Vera, Jim C. Norman, JR Infante, JT Parsons, JT Price, Juan Pablo Macagno, K Blochlinger, K Halfar, K Mesaki, K Sawamoto, L Henriksen, L Sadowski, LV Owens, M Agochiya, M Ayaki, M Freeman, M Grieco, M Miaczynska, M Roberts, M Santoro, M Therrien, M Vidal, M Vidal, Marcos Vidal, Margaret Frame, Marshall S. Horwitz, MC Frame, ME Grether, ME Irwin, MM Bradford, P Kurada, P-I Tsai, PM Siesser, R Gleichauf, R Ohta, RD Read, RH Palmer, Ruth Palmer, S Leboulleux, S Murakami, S Rizzolio, S Sigismund, SA Speicher, SM Jhiang, SY Chen, T Das, T Matsuo, T-H Chen, W Long, WG Cance, X Zhao, Y Zheng, Yachuan Yu, Z Lu   +86 more
core   +4 more sources

The complexity of the ERK/MAP kinase pathway and the treatment of melanoma skin cancer

Frontiers in Cell and Developmental Biology, 2016
The central role played by the ERK/MAPK pathway downstream of RAS in human neoplasias is best exemplified in the context of melanoma skin cancer. Signalling through the MAPK pathway is crucial for the proliferation of melanocytes, the healthy pigment ...
Claudia eWellbrock, Imanol eArozarena
doaj   +1 more source